Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03741192
Other study ID # CPT-04-2018
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date January 2020
Est. completion date January 2026

Study information

Verified date July 2019
Source Brain Sentinel
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open label, randomized, prospective study of the impact on healthcare utilization of a surface Electromyography (sEMG) based seizure monitoring and alerting system for Veterans with seizures with upper extremity motor involvement, that are refractory to three or more antiepileptic drugs.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 58
Est. completion date January 2026
Est. primary completion date January 2021
Accepts healthy volunteers No
Gender All
Age group 22 Years and older
Eligibility Inclusion Criteria:

1. Subject is a veteran with a reported history of motor seizures (epileptic, non-epileptic or unknown) with upper extremity motor involvement, presenting with questionable spell characterization.

2. Subjects suspected of experiencing one or more spells per month.

3. Subjects has failed at least 3 anti-epileptic drugs (single or combination).

4. Male or Female between the ages 22 to 99.

5. If female and of childbearing potential, subject must agree to not become pregnant during the trial.

6. Can understand and sign written informed consent or will have a legally authorized representative (LAR) who can do so, prior to the performance of any study assessments.

7. Subject or Primary Caregiver must be competent to follow all study procedures.

8. Subject must be willing to use the Seizure Monitoring and Alerting System for a prolonged period (up to five months), for a minimum of 30 hours/ week.

Exclusion Criteria:

1. The subject cannot be pregnant, or nursing.

2. The subject cannot be sensitive or allergic to adhesives or tapes.

3. The subject may not be enrolled in another Clinical Trial.

4. The subject is homeless or in a home without a power supply.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
SPEAC System
Surface Electromyography (sEMG) based seizure monitoring and alerting system

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Brain Sentinel

Outcome

Type Measure Description Time frame Safety issue
Primary Diagnostic Impact Form Questionnaire The physician will complete this questionnaire after each 30 days of device use to determine if information acquired will change the physician's assessment of the patient's seizures and their treatment plan. Up to 5 months
Secondary Personal Impact of Epilepsy Scale (PIES) Survey The PIES survey creates a composite score that can be used to assess the quality of life of patients with epilepsy, as well as sub-scales for assessing the quality of life in specific areas of life with epilepsy. 1 year
Secondary VR-12 Survey This measure has been used in cost-effectiveness analyses and can be used to calculate quality adjusted life years (QALY). 1 year
Secondary Personal Impact of Epilepsy Scale (PIES) Survey The PIES survey creates a composite score that can be used to assess the quality of life of patients with epilepsy, as well as sub-scales for assessing the quality of life in specific areas of life with epilepsy. 5 years
Secondary VR-12 Survey This measure has been used in cost-effectiveness analyses and can be used to calculate quality adjusted life years (QALY). 5 years
Secondary VA Administrative Data Healthcare utilization, medication, and cost data will be collected to determine VA administrative data will be used to evaluate health outcomes. 1 year
Secondary VA Administrative Data VA administrative data will be used to evaluate health outcomes. 5 years
See also
  Status Clinical Trial Phase
Completed NCT03014752 - Comparison of the Effectiveness of the Outpatient Classical Ketogenic Diet and Modified Atkins Diet on Seizures Frequency, Nutritional Status and Some Biochemical Factors in Children and Adolescents With Intractable Epilepsy Phase 2/Phase 3
Terminated NCT03790436 - Betaquik as an Adjunct to Dietary Management of Epilepsy in Adults on the Modified Atkins Diet N/A
Completed NCT05503511 - Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects Phase 1
Enrolling by invitation NCT04286776 - Memory Retrieval and Encoding Investigated by Neural Stimulation N/A
Completed NCT04763070 - Ciprofloxacin in Drug-resistant Epilepsy N/A
Completed NCT03403907 - The Effect of Probiotic Supplementation in Drug-resistant Epilepsy Patients N/A
Recruiting NCT04158531 - REC2Stim as a Treatment for Refractory Epilepsy in the Primary Sensorimotor Cortex. N/A
Recruiting NCT03289572 - Microgrid II - Electrocorticography Signals for Human Hand Prosthetics
Enrolling by invitation NCT05332990 - Multicenter Comparison of Interictal HFO as a Predictor of Seizure Freedom
Recruiting NCT04325360 - Effects of Transcranial Direct Current Stimulation (tDCS) for the Treatment of Refractory Epilepsy N/A
Active, not recruiting NCT05727943 - Add-on Clioquinol in Drug-resistant Childhood Epilepsy: an Exploratory Study Phase 2
Recruiting NCT04649008 - Localizing Epileptic Networks Using MRI and iEEG Early Phase 1
Active, not recruiting NCT03916848 - Novel Network Analysis of Intracranial Stereoelectroencephalography N/A
Completed NCT03646240 - ABI-009 (Nab-rapamycin) for Surgically-Refractory Epilepsy (RaSuRE) Phase 1
Recruiting NCT03857074 - Effects of Green Light Exposure on Epileptic Spikes in Patients With Refractory Epilepsy N/A
Enrolling by invitation NCT03702127 - TMS - Intracranial Electrodes N/A
Recruiting NCT05015868 - Contribution of Genetics, Non-invasive Methods and Neuropsychology in Focal Cryptogenic Epilepsies N/A
Enrolling by invitation NCT06138808 - 5-SENSE Score Validation Study
Enrolling by invitation NCT05248269 - Thermocoagulation in Drug Resistant Focal Epilepsy N/A
Completed NCT04399954 - Evaluation of Ketoflo N/A